Comprehensive Stock Comparison
Compare Coherus Oncology, Inc. (CHRS) vs Apple Inc. (AAPL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AAPL | 6.4% revenue growth vs CHRS's 3.8% |
| Value | CHRS | Lower P/E (6.7x vs 31.1x) |
| Quality / Margins | CHRS | 185.4% net margin vs AAPL's 27.0% |
| Stability / Safety | AAPL | Beta 1.28 vs CHRS's 1.33 |
| Dividends | AAPL | 0.4% yield; 14-year raise streak; CHRS pays no meaningful dividend |
| Momentum (1Y) | CHRS | +50.5% vs AAPL's +9.7% |
| Efficiency (ROA) | AAPL | 31.1% ROA vs CHRS's 30.0%, ROIC 64.5% vs -85.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Coherus Oncology is a biopharmaceutical company that develops and commercializes cancer immunotherapies and biosimilars. It generates revenue primarily from sales of its oncology biosimilars — including UDENYCA (a Neulasta biosimilar) and CIMERLI (a Lucentis biosimilar) — along with its novel immunotherapy LOQTORZI, with oncology products driving the majority of sales. The company's competitive advantage lies in its dual focus on lower-cost biosimilars that expand patient access and novel immunotherapies that target specific cancer pathways.
Apple is a technology giant that designs and sells premium consumer electronics — most famously the iPhone — along with related software and services. It generates revenue primarily from hardware sales (roughly 80% of total) and a fast-growing services segment (around 20%) that includes the App Store, subscriptions, and licensing. Its key competitive advantage is a powerful ecosystem that locks users into its hardware, software, and services through seamless integration and high switching costs.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AAPL leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). CHRS leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
AAPL is the larger business by revenue, generating $435.6B annually — 5212.7x CHRS's $84M. CHRS is the more profitable business, keeping 185.4% of every revenue dollar as net income compared to AAPL's 27.0%. On growth, AAPL holds the edge at +15.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CHRSCoherus Oncology,… | AAPLApple Inc. |
|---|---|---|
| RevenueTrailing 12 months | $84M | $435.6B |
| EBITDAEarnings before interest/tax | -$173M | $152.9B |
| Net IncomeAfter-tax profit | $155M | $117.8B |
| Free Cash FlowCash after capex | -$90M | $123.3B |
| Gross MarginGross profit ÷ Revenue | +47.8% | +47.3% |
| Operating MarginEBIT ÷ Revenue | -2.1% | +32.4% |
| Net MarginNet income ÷ Revenue | +185.4% | +27.0% |
| FCF MarginFCF ÷ Revenue | -107.9% | +28.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -83.7% | +15.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.3% | +18.3% |
Valuation Metrics
At 6.7x trailing earnings, CHRS trades at a 81% valuation discount to AAPL's 35.4x P/E.
| Metric | CHRSCoherus Oncology,… | AAPLApple Inc. |
|---|---|---|
| Market CapShares × price | $194M | $3.88T |
| Enterprise ValueMkt cap + debt − cash | $338M | $3.97T |
| Trailing P/EPrice ÷ TTM EPS | 6.68x | 35.41x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 31.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.98x |
| EV / EBITDAEnterprise value multiple | — | 27.45x |
| Price / SalesMarket cap ÷ Revenue | 0.73x | 9.33x |
| Price / BookPrice ÷ Book value/share | — | 53.76x |
| Price / FCFMarket cap ÷ FCF | — | 39.33x |
Profitability & Efficiency
CHRS delivers a 176.6% return on equity — every $100 of shareholder capital generates $177 in annual profit, vs $134 for AAPL. On the Piotroski fundamental quality scale (0–9), AAPL scores 7/9 vs CHRS's 5/9, reflecting strong financial health.
| Metric | CHRSCoherus Oncology,… | AAPLApple Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +176.6% | +133.5% |
| ROA (TTM)Return on assets | +30.0% | +31.1% |
| ROICReturn on invested capital | -85.3% | +64.5% |
| ROCEReturn on capital employed | -48.2% | +69.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | — | 1.67x |
| Net DebtTotal debt minus cash | $144M | $89.7B |
| Cash & Equiv.Liquid assets | $126M | $33.5B |
| Total DebtShort + long-term debt | $270M | $123.3B |
| Interest CoverageEBIT ÷ Interest expense | -14.50x | — |
Total Returns (with DRIP)
A $10,000 investment in AAPL five years ago would be worth $21,049 today (with dividends reinvested), compared to $1,042 for CHRS. Over the past 12 months, CHRS leads with a +50.5% total return vs AAPL's +9.7%. The 3-year compound annual growth rate (CAGR) favors AAPL at 21.9% vs CHRS's -37.3% — a key indicator of consistent wealth creation.
| Metric | CHRSCoherus Oncology,… | AAPLApple Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +21.9% | -2.4% |
| 1-Year ReturnPast 12 months | +50.5% | +9.7% |
| 3-Year ReturnCumulative with dividends | -75.3% | +81.2% |
| 5-Year ReturnCumulative with dividends | -89.6% | +110.5% |
| 10-Year ReturnCumulative with dividends | -88.2% | +1027.4% |
| CAGR (3Y)Annualised 3-year return | -37.3% | +21.9% |
Risk & Volatility
AAPL is the less volatile stock with a 1.28 beta — it tends to amplify market swings less than CHRS's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AAPL currently trades 91.5% from its 52-week high vs CHRS's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CHRSCoherus Oncology,… | AAPLApple Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.33x | 1.28x |
| 52-Week HighHighest price in past year | $2.62 | $288.61 |
| 52-Week LowLowest price in past year | $0.71 | $169.21 |
| % of 52W HighCurrent price vs 52-week peak | +63.8% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 44.1 | 57.5 |
| Avg Volume (50D)Average daily shares traded | 2.6M | 40.9M |
Analyst Outlook
Wall Street rates CHRS as "Buy" and AAPL as "Buy". Consensus price targets imply 260.5% upside for CHRS (target: $6) vs 14.7% for AAPL (target: $303). AAPL is the only dividend payer here at 0.39% yield — a key consideration for income-focused portfolios.
| Metric | CHRSCoherus Oncology,… | AAPLApple Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $6.02 | $303.11 |
| # AnalystsCovering analysts | 16 | 109 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 14 |
| Dividend / ShareAnnual DPS | — | $1.03 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | 100 | 10.48 | -89.5% |
| Apple Inc. (AAPL) | 100 | 361.46 | +261.5% |
Apple Inc. (AAPL) returned +110% over 5 years vs Coherus Oncology, I… (CHRS)'s -90%. A $10,000 investment in AAPL 5 years ago would be worth $21,049 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | $190M | $267M | +40.4% |
| Apple Inc. (AAPL) | $215.6B | $416.2B | +93.0% |
Apple Inc.'s revenue grew from $215.6B (2016) to $416.2B (2025) — a 7.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | -67.0% | 10.7% | +115.9% |
| Apple Inc. (AAPL) | 21.2% | 26.9% | +27.0% |
Apple Inc.'s net margin went from 21% (2016) to 27% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | 14.6 | 5.5 | -62.3% |
| Apple Inc. (AAPL) | 18.4 | 36.4 | +97.8% |
Coherus Oncology, Inc. has traded in a 6x–15x P/E range over 3 years; current trailing P/E is ~7x. Apple Inc. has traded in a 13x–41x P/E range over 9 years; current trailing P/E is ~35x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | -3.04 | 0.25 | +108.2% |
| Apple Inc. (AAPL) | 2.08 | 7.46 | +258.7% |
Apple Inc.'s EPS grew from $2.08 (2016) to $7.46 (2025) — a 15% CAGR.
Chart 6Free Cash Flow — 5 Years
Coherus Oncology, Inc. generated $-20M FCF in 2024 (+47% vs 2021). Apple Inc. generated $99B FCF in 2025 (+6% vs 2021).
CHRS vs AAPL: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CHRS or AAPL a better buy right now?
Coherus Oncology, Inc. (CHRS) offers the better valuation at 6.7x trailing P/E, making it the more compelling value choice. Analysts rate Coherus Oncology, Inc. (CHRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CHRS or AAPL?
On trailing P/E, Coherus Oncology, Inc. (CHRS) is the cheapest at 6.7x versus Apple Inc. at 35.4x.
03Which is the better long-term investment — CHRS or AAPL?
Over the past 5 years, Apple Inc. (AAPL) delivered a total return of +110.5%, compared to -89.6% for Coherus Oncology, Inc. (CHRS). A $10,000 investment in AAPL five years ago would be worth approximately $21K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AAPL returned +1027% versus CHRS's -88.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CHRS or AAPL?
By beta (market sensitivity over 5 years), Apple Inc. (AAPL) is the lower-risk stock at 1.28β versus Coherus Oncology, Inc.'s 1.33β — meaning CHRS is approximately 4% more volatile than AAPL relative to the S&P 500.
05Which has better profit margins — CHRS or AAPL?
Apple Inc. (AAPL) is the more profitable company, earning 26.9% net margin versus 10.7% for Coherus Oncology, Inc. — meaning it keeps 26.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AAPL leads at 32.0% versus -41.8% for CHRS. At the gross margin level — before operating expenses — CHRS leads at 56.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CHRS or AAPL more undervalued right now?
Analyst consensus price targets imply the most upside for CHRS: 260.5% to $6.02.
07Which pays a better dividend — CHRS or AAPL?
In this comparison, AAPL (0.4% yield) pays a dividend. CHRS does not pay a meaningful dividend and should not be held primarily for income.
08Is CHRS or AAPL better for a retirement portfolio?
For long-horizon retirement investors, Apple Inc. (AAPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.28), +1027% 10Y return). Both have compounded well over 10 years (AAPL: +1027%, CHRS: -88.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CHRS and AAPL?
These companies operate in different sectors (CHRS (Healthcare) and AAPL (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced. In terms of investment character: CHRS is a small-cap deep-value stock; AAPL is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.